» Articles » PMID: 21570138

Gender-related Differences in Presentation, Treatment and Long-term Outcome in Patients with First-diagnosed Atrial Fibrillation and Structurally Normal Heart: the Belgrade Atrial Fibrillation Study

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2011 May 17
PMID 21570138
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several studies have investigated gender-related differences in atrial fibrillation (AF), but limited data are available in relation to gender-related differences in presentation, treatment and long-term outcomes of patients with first-diagnosed AF and structurally normal heart.

Objective: To compare gender-related clinical characteristics, presentation, treatment and long-term outcomes in a cohort of patients with first-diagnosed non-valvular AF and a structurally normal heart, following a 10-year follow-up.

Methods: Observational cohort study of patients with AF between 1992 and 2007.

Results: Of 862 patients (mean age 52.2±12.1 years), 315 (36.5%) were female. Paroxysmal AF and hypertension were significantly more prevalent in females, while persistent AF was more common amongst males (all p<0.001). Female patients were more symptomatic (p=0.002). After a mean follow-up of 10.1±6.1 years, more male patients developed tachycardiomyopathy (6.0% vs. 1.9%, p=0.02). In multivariate analysis, male gender remained significantly associated with tachycardiomyopathy (HR 3.1, 95% CI: 1.3-7.4, p=0.012). The rate of transition to permanent AF, thromboembolism, hemorrhage, all-cause mortality, cardiovascular and sudden death did not significantly differ between male and female patients.

Conclusions: Gender differences are evident in AF. Male patients were less asymptomatic or more frequently developed persistent AF. Male patients were also at higher risk of tachycardiomyopathy, suggesting that these patients require more attention to rate control during follow-up.

Citing Articles

Association of left pulmonary vein trunk and subclinical atrial fibrillation in patients with cardiac implantable electronic device.

Kashiwagi M, Kuroi A, Higashimoto N, Mori K, Terada K, Katayama Y Heart Vessels. 2024; 39(12):1036-1044.

PMID: 38822844 DOI: 10.1007/s00380-024-02423-4.


Obesity effect on newly diagnosed and recurrent post-ablation atrial fibrillation: a systematic review and meta-analysis.

Folli F, Centofanti L, Magnani S, Tagliabue E, Bignotto M, La Sala L J Endocrinol Invest. 2023; 47(5):1051-1066.

PMID: 37962809 DOI: 10.1007/s40618-023-02225-x.


Gender-Based Clinical, Therapeutic Strategies and Prognosis Differences in Atrial Fibrillation.

Quesada A, Quesada-Ocete J, Quesada-Ocete B, Moral-Ronda V, Jimenez-Bello J, Rubini-Costa R J Cardiovasc Dev Dis. 2023; 10(10).

PMID: 37887881 PMC: 10607185. DOI: 10.3390/jcdd10100434.


Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response.

Rago A, Pirozzi C, DAndrea A, Di Micco P, Papa A, DOnofrio A Medicina (Kaunas). 2023; 59(2).

PMID: 36837457 PMC: 9963174. DOI: 10.3390/medicina59020254.


Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database.

Subramanya V, Claxton J, Lutsey P, MacLehose R, Chen L, Chamberlain A BMC Cardiovasc Disord. 2021; 21(1):598.

PMID: 34915858 PMC: 8679994. DOI: 10.1186/s12872-021-02419-2.